Pfizer Limited's Board of Directors has declared and approved a final dividend of ₹35/- per equity share of ₹10 each (350%), a special dividend of ₹100 per equity share of ₹10 each and a special dividend of ₹30 per equity share of ₹10 for the financial year ending March 31, 2025.
The company's Board of Directors, at their meeting held on May 19, 2025, recommended a total dividend of ₹165 per equity share of face value ₹10 each (1,650%) for the financial year ended March 31, 2025.
This includes a final dividend of ₹35 (350%), a special dividend of ₹100 (1,000%) to commemorate Pfizer’s 75th year in India, and an additional special dividend of ₹30 (300%) arising from the gain on the transfer of leasehold land and the building constructed on it.
The company has set July 9, 2025, as the record date to determine the eligibility of members for receiving the final dividend.
For the financial year ended March 2025, the company reported net sales of ₹2,128 crore, a slight increase from ₹2,081 crore in March 2024. Profit after taxation saw a notable rise to ₹768 crore in FY25, compared to ₹551 crore in the previous year, reflecting profitability growth.
On July 7, 2025, Pfizer share price opened at ₹5,820.00 and closed at ₹5,835.00, up by 0.88%. The stock price touched its day’s high at ₹5,851.50.
Also Read: Best Pharma Stocks in July 2025!
Pfizer Ltd is involved in the manufacturing, marketing, trading, and export of pharmaceutical products. The company produces these products at its own facility as well as through various third-party or contract manufacturers located across India. Its products are primarily distributed within the country through independent distributors.
The company's last dividend declaration was a final dividend of ₹35 per share, with a record date of August 21, 2024. With the newly approved interim dividend, shareholders can anticipate continued returns.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 8, 2025, 8:29 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
